1. Characterizing the genomic landscape through the lens of FOLR1 status in low and high grade serous ovarian carcinoma

  2. DIRAS3 induces autophagy and enhances sensitivity to anti-autophagic therapy in KRAS-driven pancreatic and ovarian carcinomas

  3. ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease

  4. Folate receptor alpha expression in low-grade serous ovarian cancer: Exploring new therapeutic possibilities

  5. Following the folate receptor: Expanding targeted treatment options in low grade serous ovarian carcinoma

  6. GOG-3097/ENGOT-ov81/GTG-UK/RAMP 301: a phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator's choice of treatment in patients with recurrent low grade serous ovarian cancer

  7. High-throughput drug screening identifies novel therapeutics for Low Grade Serous Ovarian Carcinoma

  8. High throughput screening identifies dasatinib as synergistic with trametinib in low grade serous ovarian carcinoma

  9. Hyperthermic intraperitoneal chemotherapy for recurrent ovarian cancer (CHIPOR): a randomised, open-label, phase 3 trial

  10. Impact of metformin, statins, and beta blockers on survival in patients with primary ovarian cancer: combined analysis of four prospective trials of AGO-OVAR and ENGOT/GCIG collaborators

  11. Mirvetuximab soravtansine-gynx: first antibody/antigen-drug conjugate (ADC) in advanced or recurrent ovarian cancer

  12. Molecular Surrogate Subtypes of Ovarian and Peritoneal Low-grade Serous Carcinoma

  13. Ovarian carcinosarcoma is highly aggressive compared to other ovarian cancer histotypes

  14. Primary Cytoreduction and Survival for Patients With Less-Common Epithelial Ovarian Cancer

  15. Redefining the standard of care for low-grade serous ovarian cancer

  16. The prognostic value of MEK pathway–associated estrogen receptor signaling activity for female cancers

  17. The Role of Systematic Lymphadenectomy in Low-Grade Serous Ovarian Cancer: A Systematic Review and Meta-Analysis

  18. The survival benefit associated with complete macroscopic resection in epithelial ovarian cancer is histotype specific

Previous

2025
Next

2023